Doximity
✦ Quant Fair Value how this is computed
- Implied fair-value range of 31.00-64.66, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -39.9% below the average-multiple fair value of 47.83.
Valuation each multiple against its own 5-year range
Vs. peers Health Information Services
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Doximity (DOCS) | 5.13B | 39.90 | 5.52 | 0.00% |
| Veeva Systems (VEEV) | 43.10B | 43.64 | 5.80 | 0.00% |
| BrightSpring Health Services (BTSG) | 12.50B | 33.78 | 5.75 | 0.00% |
| Tempus AI (TEM) | 9.86B | -50.98 | 19.70 | 0.00% |
| Hinge Health (HNGE) | 8.60B | 51.68 | 28.71 | 0.00% |
| HealthEquity (HQY) | 7.84B | 34.21 | 3.94 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 49.6% below Morningstar's fair value estimate.
Fair value
Doximity Inc may seem undervalued at first glance, due to its considerable price decline over the past year. However, to account for the risk associated with a potential value trap, we have limited its rating to 3 stars. The stock currently trades at a 22% discount to our quantitative fair value estimate of $42.97 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The firm's solid growth increases our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 14.2% ranks in the top 30% compared with global peers. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.
Alternatively, the firm's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, ranks in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.
Economic moat
The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 20:01:27 · For reference only, not investment advice and not tailored to your situation.
Doximity discussion 0 comments